Short-term outcomes of intravitreal faricimab on refractory neovascular age-related macular degeneration patients in China

The study evaluated the efficacy of faricimab in 37 patients with refractory neovascular age-related macular degeneration (nAMD) who had previously received at least three injections of other anti-VEGF agents. After four months of treatment, visual acuity improved (LogMAR BCVA decreased from 0.82 to 0.57) and anatomical parameters showed significant improvement. Central subfield thickness decreased from 336.89 μm to 244.19 μm. The pigment epithelial detachment area decreased from 1.30 to 0.94 mm² and the choroidal neovascularization area shrank from 1.11 to 0.97 mm². Faricimab was well-tolerated with no serious adverse effects observed. In patients with isolated subretinal fluid, 66.7% achieved extended dosing intervals of 3 months or longer.